MedTrace Logo

Gastric Tolerability and Pharmacokinetics of DMMET-01

NCT00960882 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-01-30

No results posted yet for this study

Summary

The purpose of this study is to determine the gastric tolerability and the pharmacokinetics of a new drug for the treatment of type 2 diabetes, DMMET-01, in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

DMMET-01

1050.6 mg daily for 30 days

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Oscar Torres, PhD · UANL, Pharmacology and toxicology department

  • Jorge A Gonzalez, Master · Laboratorios Silanes S.A. de C.V.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960882 on ClinicalTrials.gov